- Home
- REFI vs CCCC Comparison
REFI vs CCCC Comparison
Compare REFI & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- CCCC
- Stock Information
- Founded
- REFI 2021
- CCCC 2015
- Country
- REFI United States
- CCCC United States
- Employees
- REFI N/A
- CCCC N/A
- Industry
- REFI Real Estate Investment Trusts
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- REFI Real Estate
- CCCC Health Care
- Exchange
- REFI Nasdaq
- CCCC Nasdaq
- Market Cap
- REFI 306.1M
- CCCC 405.6M
- IPO Year
- REFI 2021
- CCCC 2020
- Fundamental
- Price
- REFI $15.39
- CCCC $6.21
- Analyst Decision
- REFI Buy
- CCCC Buy
- Analyst Count
- REFI 2
- CCCC 6
- Target Price
- REFI $20.00
- CCCC $10.50
- AVG Volume (30 Days)
- REFI 73.0K
- CCCC 712.7K
- Earning Date
- REFI 11-07-2024
- CCCC 10-30-2024
- Dividend Yield
- REFI 12.22%
- CCCC N/A
- EPS Growth
- REFI N/A
- CCCC N/A
- EPS
- REFI 1.97
- CCCC N/A
- Revenue
- REFI $55,186,946.00
- CCCC $29,378,000.00
- Revenue This Year
- REFI N/A
- CCCC $39.70
- Revenue Next Year
- REFI $4.51
- CCCC N/A
- P/E Ratio
- REFI $7.81
- CCCC N/A
- Revenue Growth
- REFI 5.63
- CCCC 83.26
- 52 Week Low
- REFI $13.86
- CCCC $1.06
- 52 Week High
- REFI $17.65
- CCCC $11.88
- Technical
- Relative Strength Index (RSI)
- REFI 42.89
- CCCC 53.88
- Support Level
- REFI $15.37
- CCCC $6.02
- Resistance Level
- REFI $15.85
- CCCC $7.14
- Average True Range (ATR)
- REFI 0.13
- CCCC 0.37
- MACD
- REFI -0.00
- CCCC 0.10
- Stochastic Oscillator
- REFI 22.22
- CCCC 57.14
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.